NO821221L - 5,6-0-isoalkyliden-askorbinsyre-derivater - Google Patents
5,6-0-isoalkyliden-askorbinsyre-derivaterInfo
- Publication number
- NO821221L NO821221L NO821221A NO821221A NO821221L NO 821221 L NO821221 L NO 821221L NO 821221 A NO821221 A NO 821221A NO 821221 A NO821221 A NO 821221A NO 821221 L NO821221 L NO 821221L
- Authority
- NO
- Norway
- Prior art keywords
- ascorbic acid
- tumor
- alkyl group
- chloroethyl
- preparation according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 16
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical class ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 15
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- FVLVBPDQNARYJU-UHFFFAOYSA-N semustine Chemical compound CC1CCC(NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 3
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 21
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000012948 isocyanate Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 150000002513 isocyanates Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 150000002083 enediols Chemical class 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000000269 nucleophilic effect Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 12
- 239000007859 condensation product Substances 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 7
- 239000002168 alkylating agent Substances 0.000 abstract description 6
- 229940100198 alkylating agent Drugs 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- HBCAMHAPOVKLSH-UHFFFAOYSA-N 1,1-bis(2-chloroethyl)-3-nitrosourea Chemical compound ClCCN(CCCl)C(=O)NN=O HBCAMHAPOVKLSH-UHFFFAOYSA-N 0.000 abstract 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000000996 L-ascorbic acids Chemical class 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- -1 glyoxal Chemical class 0.000 description 5
- AIJULSRZWUXGPQ-UHFFFAOYSA-N pyruvic aldehyde Natural products CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YWRMMRQWMSKGBB-YLWLKBPMSA-N (2r)-2-[(1r)-1,2-dihydroxy-3-methylbut-2-enyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound CC(C)=C(O)[C@H](O)[C@H]1OC(=O)C(O)=C1O YWRMMRQWMSKGBB-YLWLKBPMSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OSNSWKAZFASRNG-WNFIKIDCSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;hydrate Chemical compound O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O OSNSWKAZFASRNG-WNFIKIDCSA-N 0.000 description 1
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17794080A | 1980-08-14 | 1980-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO821221L true NO821221L (no) | 1982-04-14 |
Family
ID=22650546
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO821221A NO821221L (no) | 1980-08-14 | 1982-04-14 | 5,6-0-isoalkyliden-askorbinsyre-derivater |
| NO821220A NO821220L (no) | 1980-08-14 | 1982-04-14 | Nitrosourinstoff-derivater med antitumor-aktivitet |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO821220A NO821220L (no) | 1980-08-14 | 1982-04-14 | Nitrosourinstoff-derivater med antitumor-aktivitet |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP0057700A4 (de) |
| JP (2) | JPS57501580A (de) |
| DK (2) | DK167282A (de) |
| HU (1) | HU185969B (de) |
| NO (2) | NO821221L (de) |
| WO (2) | WO1982000644A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60130582A (ja) * | 1983-12-19 | 1985-07-12 | Takeda Chem Ind Ltd | 食品用酸化防止剤，アスコルビン酸誘導体およびその製造法 |
| JPS60139619A (ja) * | 1983-12-27 | 1985-07-24 | Mutsuyuki Kochi | Ｏ−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤 |
| US5405412A (en) * | 1994-04-13 | 1995-04-11 | The Procter & Gamble Company | Bleaching compounds comprising N-acyl caprolactam and alkanoyloxybenzene sulfonate bleach activators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2539483A (en) * | 1945-03-28 | 1951-01-30 | Simon L Ruskin | Urea ascorbate and complexes containing the same and process for their manufacture |
| US3074998A (en) * | 1959-12-10 | 1963-01-22 | Shell Oil Co | Enol carbamates |
| CH495980A (de) * | 1967-02-25 | 1970-09-15 | Bayer Ag | Verfahren zur Herstellung von Benzodioxan-N-methylcarbamaten |
| DE2346305A1 (de) * | 1973-09-14 | 1975-04-03 | Basf Ag | Neue carbamate und ihre verwendung als arzneimittel |
| US4111958A (en) * | 1977-06-03 | 1978-09-05 | Pfizer Inc. | Ascorbic acid synthesis |
| US4148921A (en) * | 1977-07-13 | 1979-04-10 | Suami T | Antitumor agents |
| NL7904249A (nl) * | 1978-06-20 | 1979-12-27 | Cancer Res Nat Found | Nieuwe cyclische acetalen met cytostatische, bloed- drukverlagende en pijnstillende werking, werkwijze ter bereiding van deze verbindingen alsmede farmaceu- tische preparaten die een dergelijke verbinding bevat- ten. |
| JPS554324A (en) * | 1978-06-26 | 1980-01-12 | Kaken Pharmaceut Co Ltd | Novel glycopyranosidoamine derivative, its preparation, and antitumor agent comprising it as active constituent |
| JP2811964B2 (ja) * | 1990-12-20 | 1998-10-15 | 富士通株式会社 | 接続相手指定方式 |
-
1981
- 1981-08-14 HU HU813004A patent/HU185969B/hu unknown
- 1981-08-14 WO PCT/US1981/001088 patent/WO1982000644A1/en not_active Application Discontinuation
- 1981-08-14 EP EP19810902235 patent/EP0057700A4/de not_active Ceased
- 1981-08-14 JP JP56502797A patent/JPS57501580A/ja active Pending
- 1981-08-14 EP EP19810902234 patent/EP0057699A4/de not_active Withdrawn
- 1981-08-14 JP JP50279881A patent/JPS57501581A/ja active Pending
- 1981-08-14 WO PCT/US1981/001089 patent/WO1982000642A1/en not_active Application Discontinuation
-
1982
- 1982-04-14 DK DK167282A patent/DK167282A/da active IP Right Grant
- 1982-04-14 NO NO821221A patent/NO821221L/no unknown
- 1982-04-14 DK DK167182A patent/DK167182A/da active IP Right Grant
- 1982-04-14 NO NO821220A patent/NO821220L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS57501581A (de) | 1982-09-02 |
| WO1982000644A1 (en) | 1982-03-04 |
| DK167282A (da) | 1982-04-14 |
| JPS57501580A (de) | 1982-09-02 |
| NO821220L (no) | 1982-04-14 |
| EP0057700A1 (de) | 1982-08-18 |
| WO1982000642A1 (en) | 1982-03-04 |
| HU185969B (en) | 1985-04-28 |
| EP0057699A1 (de) | 1982-08-18 |
| EP0057700A4 (de) | 1982-11-17 |
| DK167182A (da) | 1982-04-14 |
| EP0057699A4 (de) | 1982-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4960790A (en) | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof | |
| US5180722A (en) | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs | |
| DE69919695T2 (de) | Texaphyrin-konjugate und ihre anwendiung | |
| EP0532348B1 (de) | Tramadol N-Oxid, dessen Enantiomere und Zusammensetzungen davon, und deren Verwendung | |
| US5434256A (en) | Diamine platinum complexes as antitumor agents | |
| Paget et al. | Synthesis and in Vitro Activity of Some Aryl Diaziridines as Potential Monoamine Oxidase Inhibitors1a-c | |
| JPH08506812A (ja) | 抗腫瘍剤としてのアシルフルベン類似体 | |
| NO821221L (no) | 5,6-0-isoalkyliden-askorbinsyre-derivater | |
| KR100406736B1 (ko) | 나프토퀴논계 화합물을 포함하는 항암제 | |
| JPS6350347B2 (de) | ||
| EP0041792B1 (de) | Platinverbindungen mit Antitumor- oder Antimikrobial-Aktivität und diese enthaltende pharmazeutische Zubereitungen | |
| US5149697A (en) | Cobalt porphyrin pharmaceutical compositions | |
| US4125704A (en) | Phenyl-substituted rubidazone analogs | |
| US4017636A (en) | Esters of γ-glutamyl amide of dopamine | |
| US4423236A (en) | 5,6,-0-Isoalkylidene ascorbic acid derivatives | |
| JPH06501032A (ja) | 薬剤組成物 | |
| CN114177177A (zh) | 一种乏氧肿瘤选择性激活前药的制备方法 | |
| Lyttle et al. | 5-Bis (2-Chloroethyl) Aminouracil, a New Anti-tumor Agent | |
| GB2050364A (en) | Bis (4-demethoxydaunorubicin) dihydrazone derivatives and pharmacologically acceptable salts thereof | |
| US4686215A (en) | Pharmaceutical composition and method for treating tumors susceptible to 2-carbamoylaziridine | |
| EP0923932B1 (de) | Zusammensetzung enthaltend ein antitumormittel | |
| US4416878A (en) | [8-(Dialkylamino alkoxy)-caffeine]-platinum complex compounds and pharmaceutical products containing the same | |
| CN113773356B (zh) | 一种胡黄连苷ii衍生物及其制备方法和应用 | |
| EP0072760B1 (de) | Fluorierte Diaminohepten- und -heptin-Derivate | |
| US3947590A (en) | Compositions and methods of increasing renal blood flow with gamma-glutamyl amide of dopamine |